![Justin Gary Claeys](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Justin Gary Claeys
Director Ejecutivo en AMGEN GmbH .
Cargos activos de Justin Gary Claeys
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Amgen Ltd.
![]() Amgen Ltd. Miscellaneous Commercial ServicesCommercial Services Amgen Ltd. operates as a biotechnology firm. It engages in the research and development of human therapeutics to treat illnesses. The company was founded on March 1, 1989 and is headquartered in Cambridge, the United Kingdom. | Director/Miembro de la Junta | 20/04/2018 | - |
AMGEN GmbH
![]() AMGEN GmbH BiotechnologyHealth Technology AMGEN GmbH develops, manufactures, and markets human therapeutics based on cellular biology. It was established to help sell and distribute biotechnical therapies for the treatment of such ailments as chemotherapy side effects, chronic kidney failure, and rheumatoid arthritis. Among the group's products are Epogen & Aranesp for the treatment of anemia in people with chronic kidney disease; Neupogen & Neulasta to help restore white blood cell counts for cancer patients and Enbrel for the treatment of psoriasis and rheumatoid arthritis. The company was founded in 1980 and is headquartered in Munich, Germany. | Director Ejecutivo | - | - |
Historial de carrera de Justin Gary Claeys
Antiguos cargos conocidos de Justin Gary Claeys.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Amgen Research (Munich) GmbH
![]() Amgen Research (Munich) GmbH Metal FabricationProducer Manufacturing Part of Amgen, Inc., Amgen Research (Munich) GmbH is a biotechnology company based in Munich, Germany. The company has over 850 employees working at two locations in Germany. Amgen Scholars Europe Programs offer practical research experience to 100 students from all over Europe every summer. The company utilizes biotechnological possibilities to develop innovative treatments for diseases. The company continuously develops new substances to provide biopharmaceuticals to patients worldwide with serious illnesses. The CEOs of the company are Peter Kufer and Robert Saller. Amgen Research (Munich was acquired by ECKA Granulate GmbH & Co. KG from Aurubis AG on June 13, 2002. | Director Ejecutivo | - | - |
Estadísticas
Internacional
Alemania | 3 |
Reino Unido | 2 |
Operativa
Chief Executive Officer | 2 |
Director/Board Member | 1 |
Sectorial
Commercial Services | 2 |
Health Technology | 2 |
Producer Manufacturing | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 3 |
---|---|
Amgen Ltd.
![]() Amgen Ltd. Miscellaneous Commercial ServicesCommercial Services Amgen Ltd. operates as a biotechnology firm. It engages in the research and development of human therapeutics to treat illnesses. The company was founded on March 1, 1989 and is headquartered in Cambridge, the United Kingdom. | Commercial Services |
AMGEN GmbH
![]() AMGEN GmbH BiotechnologyHealth Technology AMGEN GmbH develops, manufactures, and markets human therapeutics based on cellular biology. It was established to help sell and distribute biotechnical therapies for the treatment of such ailments as chemotherapy side effects, chronic kidney failure, and rheumatoid arthritis. Among the group's products are Epogen & Aranesp for the treatment of anemia in people with chronic kidney disease; Neupogen & Neulasta to help restore white blood cell counts for cancer patients and Enbrel for the treatment of psoriasis and rheumatoid arthritis. The company was founded in 1980 and is headquartered in Munich, Germany. | Health Technology |
Amgen Research (Munich) GmbH
![]() Amgen Research (Munich) GmbH Metal FabricationProducer Manufacturing Part of Amgen, Inc., Amgen Research (Munich) GmbH is a biotechnology company based in Munich, Germany. The company has over 850 employees working at two locations in Germany. Amgen Scholars Europe Programs offer practical research experience to 100 students from all over Europe every summer. The company utilizes biotechnological possibilities to develop innovative treatments for diseases. The company continuously develops new substances to provide biopharmaceuticals to patients worldwide with serious illnesses. The CEOs of the company are Peter Kufer and Robert Saller. Amgen Research (Munich was acquired by ECKA Granulate GmbH & Co. KG from Aurubis AG on June 13, 2002. | Producer Manufacturing |
- Bolsa de valores
- Insiders
- Justin Gary Claeys
- Experiencia